
Shandong Weigao Group Medical Polymer Company Limited
1066.HKHKSEHealthcareMedical - Instruments & Supplies
Latest quote
HK$3.425
−HK$0.06 · -1.72%
1066.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteShandong Weigao Group Medical Polymer Company Limited, founded in 2000 and situated in Weihai, People's Republic of China, specializes in the research, development, production, and distribution of disposable medical devices across mainland China. The company structures its extensive operations into several core divisions, including Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and other specialized segments. Its comprehensive product range covers a vast array of essential healthcare items. This includes devices for both vascular and non-vascular access, such as infusion sets, syringes, and specialized puncture needles, alongside various clinical collection kits. Shandong Weigao also provides solutions for wound care, offering sutures, healing dressings, cleaning products, and support devices for non-vascular catheters. In the realm of blood management, it supplies equipment for collection, storage, separation, and sterilization. The company is also a manufacturer of prefilled and pre-flush syringes, as well as instruments for blood collection and glucose monitoring. Its portfolio further extends to anesthesia consumables (general, local, and auxiliary), intensive care unit (ICU) equipment, and tools for both open and minimally invasive surgical procedures. Beyond disposables, the firm is a key producer of orthopedic devices, instruments for tumor and blood vessel interventions, and advanced medical components such as implantation materials and artificial organs. It also ventures into industrial manufacturing, producing medical-grade PVC granules, various plastic packaging materials, carton boxes, automated industrial equipment and parts, molds, and hemodialysis machines, encompassing Type I, Type II, and Type III medical devices. In addition to its manufacturing activities, Shandong Weigao offers a range of supporting services. These include finance leasing and factoring, wholesale distribution of Type I, surgical, and other disposable medical products. The company also provides asset management, enterprise consulting, management advisory, and comprehensive logistics and storage solutions, while actively exporting its products to international markets. Operating under recognized brands like Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing, the company serves a diverse clientele that includes hospitals, blood banks, various other medical facilities, and a broad network of distributors.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Rinan Cong
- Listed since
- Feb 27, 2004
- Employees
- 13,307
Market position
Day range
Current HK$3.425
52-week range
Current HK$3.425
- Open
- HK$3.59
- Previous close
- HK$3.485
- Volume
- 7.55M
- 0.33× average
- Average volume
- 22.99M
- Average daily volume
- Market cap
- 15.23B HKD
- Beta
- 0.37
- Market reference 1
- 50-day average
- HK$3.3369
- +2.64% above average
- 200-day average
- HK$4.2944
- -20.25% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 17.77B CNY
- P/E (TTM)
- 8.4×
- P/B (TTM)
- 0.57×
- P/S (TTM)
- 0.98×
- EV / EBITDA
- 6.46×
- Earnings yield
- 7.76%
- Free cash flow yield
- 8.27%
- Dividend yield
- 5.11%
Profitability & efficiency
- Gross margin
- 47.26%
- Operating margin
- 12.69%
- Net margin
- 12.04%
- Return on equity
- 6.68%
- Return on assets
- 4.47%
- Return on invested capital
- 4.60%
Financial health
- Debt / equity
- 0.25×
- Current ratio
- 3.78×
- Altman Z-score
- 3.19
- Piotroski F-score
- 5 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 13.39B CNY | 13.09B CNY | 13.23B CNY | 13.62B CNY | 13.15B CNY |
| Cost of goods sold | 7.06B CNY | 6.51B CNY | 6.59B CNY | 6.51B CNY | 5.88B CNY |
| Gross profit | 6.33B CNY | 6.58B CNY | 6.64B CNY | 7.31B CNY | 7.35B CNY |
| Research and development | 793.99M CNY | 625.23M CNY | 731.38M CNY | 546.55M CNY | 492.13M CNY |
| Selling, general, and administrative | 3.83B CNY | 3.63B CNY | 3.83B CNY | 3.54B CNY | 3.77B CNY |
| Operating expenses | 4.63B CNY | 4.19B CNY | 4.35B CNY | 3.97B CNY | 4.15B CNY |
| Interest income | 183.55M CNY | 230.42M CNY | 235.68M CNY | 181.41M CNY | 143.94M CNY |
| Interest expense | 249.23M CNY | 249.57M CNY | 272.97M CNY | 191.4M CNY | 140.4M CNY |
| Depreciation and amortization | 906.26M CNY | 869.38M CNY | 911.7M CNY | 803.14M CNY | 736.67M CNY |
| Operating income | 1.7B CNY | 2.39B CNY | 2.04B CNY | 2.92B CNY | 2.89B CNY |
| Net income | 1.61B CNY | 2.07B CNY | 2B CNY | 2.76B CNY | 2.28B CNY |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 43%
- 3 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -1.98%
- 7 comparable reports
- Latest EPS result
- 0.14
- Estimate 0.2 · Miss by 27.76%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
HK$0.2405
2025 complete year+37.4% since 2021
2026 partial: HK$0.0688
HK$0.175
2,021
HK$0.172
2,022
HK$0.167
2,023
HK$0.2044
2,024
HK$0.2405
2,025
HK$0.0688
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 2, 2026 | HK$0.0688Semi-Annual | Jun 3, 2026 | Jul 10, 2026 |
Dividend | Oct 21, 2025 | HK$0.1061Semi-Annual | Oct 22, 2025 | Nov 21, 2025 |
Dividend | Jun 2, 2025 | HK$0.1344Semi-Annual | Jun 3, 2025 | Jul 11, 2025 |
Dividend | Oct 18, 2024 | HK$0.1009Semi-Annual | Oct 21, 2024 | Nov 22, 2024 |
Dividend | Jun 3, 2024 | HK$0.1035Semi-Annual | Jun 4, 2024 | Jul 12, 2024 |
Dividend | Oct 19, 2023 | HK$0.08Semi-Annual | Oct 20, 2023 | Nov 24, 2023 |
Ex-dividend Jun 2, 2026
HK$0.0688
Semi-Annual
Record Jun 3, 2026 · Payment Jul 10, 2026
Ex-dividend Oct 21, 2025
HK$0.1061
Semi-Annual
Record Oct 22, 2025 · Payment Nov 21, 2025
Ex-dividend Jun 2, 2025
HK$0.1344
Semi-Annual
Record Jun 3, 2025 · Payment Jul 11, 2025
Ex-dividend Oct 18, 2024
HK$0.1009
Semi-Annual
Record Oct 21, 2024 · Payment Nov 22, 2024
Ex-dividend Jun 3, 2024
HK$0.1035
Semi-Annual
Record Jun 4, 2024 · Payment Jul 12, 2024
Ex-dividend Oct 19, 2023
HK$0.08
Semi-Annual
Record Oct 20, 2023 · Payment Nov 24, 2023
1066.HK peers
Continue in GoAI
Research 1066.HKresearch.disclaimer





